Survival of Patients With mRCC Continues to Improve in the Targeted Therapy Era

Using the SEER (Surveillance, Epidemiology, and End Results) registry (2001–2014) from the US NCI (National Cancer Institute) , 15,444 patients with mRCC were identified to evaluate the effect of diagnosis year on cancer-specific mortality. Of these patients, 41%, 28.7%, and 30.3% were diagnosed in the contemporary (2010–2014), intermediate (2006–2009), and historical (2001–2005) years, respectively. The 24-month cancer-specific mortality rates were 61%, 63.7%, and 67.3%, respectively. This study indicates "the introduction of new therapeutic agents led to decreased cancer-specific mortality over the study time; however, this effect was only seen in patients with clear-cell mRCC".
http://www.practiceupdate.com/content/survival-of-patients-with-mrcc-continues-to-improve-in-the-targeted-therapy-era/58697/37/10/1